Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy in treating patients who have stage II or stage III oropharyngeal cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radiation Therapy Oncology Group
• Collaborator: National Cancer Institute (NCI)

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven stage II or III (T1-T2, N0-N1) squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or palate)

• Lymph nodes in both sides of neck at risk of metastatic disease and require radiotherapy

• Patients upstaged by imaging to N2 are eligible

• Measurable or evaluable disease

• Greater than 1 cm in one dimension or with necrotic regions if by CT or MRI scan

• Surgery of the primary tumor or lymph nodes limited to incisional or excisional biopsies

• No distant metastases

PATIENT CHARACTERISTICS:

Age:

• Over 18

Performance status:

• Zubrod 0-1

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• No active untreated infection

• No other malignancy within the past 5 years except nonmelanoma skin cancer or a carcinoma not of head or neck origin

• No concurrent major medical or psychiatric illness that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• More than 3 months since prior chemotherapy

• No concurrent chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• No prior head or neck radiotherapy

Surgery:

• See Disease Characteristics

Other:

• No other concurrent treatment for head and neck cancer

• No prophylactic amifostine or pilocarpine